Biogen IDEC Inc. (BIIB-Q) Stock Predictions - Stockchase
WATCH LIST
23
Biogen IDEC Inc. (BIIB-Q)

ON STOCKCHASE SINCE May 2004

biotechnology/pharmaceutical

Biogen IDEC Inc.

BIIB-Q

12 watching          
Join the Discussion

Biogen IDEC Inc. (BIIB-Q) SAVE Mar, 20, 2019, 2:32 pm

322.81 0.95 (0.29%)

About Biogen IDEC Inc. (BIIB-Q)

Biogen, Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurodegenerative, ... More at Wikipedia

What the experts are saying about BIIB-Q



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
Biogen IDEC Inc.(BIIB-Q) 

July 17, 2018

A large bio-pharma. They enjoyed a recent jump in the stock price had to do with seeing promising results from a phase 2 trial drug treating Alzheimer's. If this drug ultimately passes, it would be an multi-billion-dollar opportunity. Free cash flow is a high 7%. They'll likely make an acqusition with all this cash to deepend their portfolio. (Analysts' price target: $365.00)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A large bio-pharma. They enjoyed a recent jump in the stock price had to do with seeing promising results from a phase 2 trial drug treating Alzheimer's. If this drug ultimately passes, it would be an multi-billion-dollar opportunity. Free cash flow is a high 7%. They'll likely make an acqusition with all this cash to deepend their portfolio. (Analysts' price target: $365.00)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$354.980
Owned Owned
Yes

DON'T BUY

He Prefers VRTX-Q.  You need to invest in the most innovative companies in this sector.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He Prefers VRTX-Q.  You need to invest in the most innovative companies in this sector.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$266.440
Owned Owned
No

PAST TOP PICK
Biogen IDEC Inc.(BIIB-Q) 

March 14, 2018

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A situation where the market is nervous, the stock slips, which then creates opportunity. Investors won't pay these kinds of multiples out of uncertainty. Biogen is focussed on developing solutions for MS; their Alzheimer's drug is in phase 3 testing, which he personally hopes works. Be patient. BIIB will bounce around with failed drug tests, but this company will yield winning drugs.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$285.720
Owned Owned
Yes

BUY
Biogen IDEC Inc.(BIIB-Q) 

March 14, 2018

He loves when good companies pullback in price.  He would be tempted to buy here and more if it fell to $240.  His model price is $402.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He loves when good companies pullback in price.  He would be tempted to buy here and more if it fell to $240.  His model price is $402.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brian Acker, CA

Chief Exec, Acker Finley Inc....

Price Price
$285.720
Owned Owned
Unknown

PARTIAL SELL
Biogen IDEC Inc.(BIIB-Q) 

October 2, 2017

Seasonal strength is from May until the end of September.  It is an opportunity to take some money off the table.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Seasonal strength is from May until the end of September.  It is an opportunity to take some money off the table.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Vialoux

Research A, TimingTheMarket.CA &...

Price Price
$316.170
Owned Owned
Unknown

DON'T BUY
Biogen IDEC Inc.(BIIB-Q) 

September 14, 2017

It has a large franchise in MS which comprises 75% of their business.  He is seeing potential threat to this franchise from two companies.  Their Alzheimer’ drug comes to trial in 2019 and has high risk.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

It has a large franchise in MS which comprises 75% of their business.  He is seeing potential threat to this franchise from two companies.  Their Alzheimer’ drug comes to trial in 2019 and has high risk.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$323.660
Owned Owned
Unknown

COMMENT
Biogen IDEC Inc.(BIIB-Q) 

June 28, 2017

US healthcare for the long-term? As opposed to picking just one stock in a sector, your best bet probably is an ETF. If you are looking for an individual stock, one that he holds is Biogen. It is quite cheap relative to its ability to grow earnings.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

US healthcare for the long-term? As opposed to picking just one stock in a sector, your best bet probably is an ETF. If you are looking for an individual stock, one that he holds is Biogen. It is quite cheap relative to its ability to grow earnings.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jason Mann

CIO & Co-F, Edgehill Patners...

Price Price
$274.640
Owned Owned
Yes

COMMENT

He doesn’t own this because of their concentration in the MS market. There are 2 other companies in this area with possible better drugs. He feels there are going to be very binary outcomes with no dividends. Prefers something with a little more diversity.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He doesn’t own this because of their concentration in the MS market. There are 2 other companies in this area with possible better drugs. He feels there are going to be very binary outcomes with no dividends. Prefers something with a little more diversity.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$257.920
Owned Owned
No

TOP PICK
Biogen IDEC Inc.(BIIB-Q) 

March 16, 2017

A bio pharmaceutical. If you look at the traditional Pharma space, the chemical-based companies, the bio-based companies were always out there, coming along, but basically not making a lot of money and were often single drug companies, virtually reinvesting all their cash flow. They have now matured and into much stronger growth companies than the traditional pharmas. They also have lower multiples than they did 5-6 years ago. That makes it quite attractive. (Analysts’ price target is $305.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A bio pharmaceutical. If you look at the traditional Pharma space, the chemical-based companies, the bio-based companies were always out there, coming along, but basically not making a lot of money and were often single drug companies, virtually reinvesting all their cash flow. They have now matured and into much stronger growth companies than the traditional pharmas. They also have lower multiples than they did 5-6 years ago. That makes it quite attractive. (Analysts’ price target is $305.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$278.960
Owned Owned
Yes

HOLD
Biogen IDEC Inc.(BIIB-Q) 

November 22, 2016

(Market Call Minute.) Many people thought the Biotech sector would behave better if Trump got elected. It has had a lift, but it remains to be seen if it can be followed through.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Market Call Minute.) Many people thought the Biotech sector would behave better if Trump got elected. It has had a lift, but it remains to be seen if it can be followed through.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$318.110
Owned Owned
No

BUY
Biogen IDEC Inc.(BIIB-Q) 

August 15, 2016

(Market Call Minute.) One of the better growth stories in the US biotech side. They have more of a product portfolio and they have cash. Valuation is in line with the market.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Market Call Minute.) One of the better growth stories in the US biotech side. They have more of a product portfolio and they have cash. Valuation is in line with the market.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Zechner

Chairman, J. Zechner & Assoc...

Price Price
$313.390
Owned Owned
Unknown

COMMENT
Biogen IDEC Inc.(BIIB-Q) 

June 22, 2016

Amgen (AMGN-Q), Celgene (CELG-Q) or Biogen (BIIB-Q)? These are 3 great companies. His preference would be Amgen, the leader in the space and the dominant player. This one is a great example of a mega-cap company that has a lot of pent-up interest in one of their phase III’s. Alzheimer’s hasn’t had a great success rate in drug testing, but if it does come positive, you could see some great valuation.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Amgen (AMGN-Q), Celgene (CELG-Q) or Biogen (BIIB-Q)? These are 3 great companies. His preference would be Amgen, the leader in the space and the dominant player. This one is a great example of a mega-cap company that has a lot of pent-up interest in one of their phase III’s. Alzheimer’s hasn’t had a great success rate in drug testing, but if it does come positive, you could see some great valuation.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$234.600
Owned Owned
No

PAST TOP PICK
Biogen IDEC Inc.(BIIB-Q) 

March 15, 2016

(A Top Pick March 10/15. Down 39.56%.) For about 3 years Biotech was one of the leading groups in the market. He stays in positions as long as they work, and runs Stop Losses. In July, biotech as a group rolled over and he got stopped out at about $308-$310.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick March 10/15. Down 39.56%.) For about 3 years Biotech was one of the leading groups in the market. He stays in positions as long as they work, and runs Stop Losses. In July, biotech as a group rolled over and he got stopped out at about $308-$310.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$250.330
Owned Owned
No

PAST TOP PICK
Biogen IDEC Inc.(BIIB-Q) 

February 18, 2016

(Top Pick Mar 10/15, Down 36.01%)  He got stopped out last March.  They missed a number.  He is not buying biotech right now.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Top Pick Mar 10/15, Down 36.01%)  He got stopped out last March.  They missed a number.  He is not buying biotech right now.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$259.050
Owned Owned
No

BUY on WEAKNESS
Biogen IDEC Inc.(BIIB-Q) 

July 22, 2015

Has been watching this for a little while. It doesn’t trade at an extreme valuation and they have a nice pipeline. A drug that propelled them recently was their new Alzheimer’s one that is still in testing. A very promising drug. In a short time they are going to come out with the results of a new test on it. He thinks the market will react on this, so he would be hesitant to buy in front of that. If you can buy this in the $350-$375 area, it has a lot of promise.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Has been watching this for a little while. It doesn’t trade at an extreme valuation and they have a nice pipeline. A drug that propelled them recently was their new Alzheimer’s one that is still in testing. A very promising drug. In a short time they are going to come out with the results of a new test on it. He thinks the market will react on this, so he would be hesitant to buy in front of that. If you can buy this in the $350-$375 area, it has a lot of promise.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$391.740
Owned Owned
No

Showing 1 to 15 of 23 entries
Successfully Saved Company
Successfully Saved Company